ARTICLE | Clinical News

Evizon squalamine lactate: Interim Phase II data

March 6, 2006 8:00 AM UTC

In the double-blind, U.S. Phase II trial (MSI-1256F-209) in 108 patients, the 40 mg dose of Evizon was safe and well tolerated at 24 weeks and stabilized vision in both the study eyes and the fellow e...